The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Abivax SA shares suffered a spectacular collapse on Tuesday, cratering as much as 40% in Paris and New York.

The clinical-stage drugmaker dropped highly anticipated Phase 3 maintenance data for its lead ulcerative colitis pill, obefazimod. The headline numbers revealed unmatched long-term efficacy, putting the company on a direct flight path to challenge big-pharma incumbents. However, the victory was instantly derailed by the appearance of scattered cancer cases concentrated exclusively in the high-dose cohort, spooking institutional investors and prompting an immediate, high-profile analyst downgrade.

The results from the global 44-week ABTECT maintenance study originally looked like a best-case scenario. Evaluating patients with moderately to severely active ulcerative colitis — many of whom were completely refractory, having failed multiple advanced biologic therapies — obefazimod proved to be an absolute clinical powerhouse. Patients on either the 25 mg or 50 mg once-daily oral doses achieved clinical remission rates of 50.8% and 51.3%, respectively. This stands in contrast to a meager 10.4% baseline for the placebo group, securing a placebo-adjusted remission rate of roughly 40%.

The financial wheels fell off, however, when investors opened the safety appendix. In the higher 50 mg treatment arm, investigators recorded individual diagnoses of prostate cancer, breast cancer, and colonic dysplasia — an abnormal cell progression that often acts as a precursor to malignant tumors. The high-dose cluster also flagged four separate non-melanoma skin cancer cases.

Abivax leadership and independent clinical heads moved rapidly to contextualize the safety print, explicitly stating that investigators found no evidence of a causal relationship between the drug and the malignancies. They pointed out that colonic dysplasia is an inherent risk of long-term inflammatory bowel disease, that two of the skin cancer patients carried an extensive history of malignancy, and that the average age of the skin cancer group was 62 years old, compared to a baseline of 42 for the overall trial.

The market refused to give the company the benefit of the doubt. The Paris-listed stock collapsed to €66.10, erasing billions in market value. The aggressive selloff marks a violent pivot for a darling stock that had surged nearly 1,700% over the previous year on the back of intense pharmaceutical takeover speculation.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

This data readout was supposed to be the ultimate catalyst to trigger a multi-billion-dollar bidding war among global pharmaceutical titans.

Before Tuesday's crash, industry insiders had identified Eli Lilly, AstraZeneca, Pfizer, and Takeda as prime suitors circling the French biotech. Because obefazimod operates through a novel, first-in-class mechanism as an oral miR-124 enhancer, its structural ability to maintain a 40% clinical remission rate over a year puts it at the absolute pinnacle of the inflammatory bowel disease market. It comfortably outpaces competitors like Pfizer’s Velsipity (32% remission) and sits shoulder-to-shoulder with AbbVie’s market-dominating JAK inhibitor, Rinvoq (39% remission).

The problem is that the private equity and pharmaceutical corporate development teams who execute mega-billion-dollar biotech buyouts are characteristically risk-averse. Jefferies analyst Faisal Khurshid immediately downgraded the stock from Buy to Hold, slicing his price target from $160 down to $90. Khurshid (winning rate: 50.0%) argued that even if the malignancy signal is completely unrelated statistical noise, it introduces a major regulatory overhang that cannot be easily dismissed by potential buyers, especially with zero other valuation-inflecting data events scheduled for the next year.

However, a vocal contingent of Wall Street analysts is pitching this 40% drop as a textbook buy-the-dip opportunity. Bullish notes from Stifel and Citizens JMP point out that the global drug market is highly accustomed to navigating malignancy red flags in the auto-immune space. AbbVie’s Rinvoq carries a strict FDA black-box safety warning for all-cause mortality and malignancy, yet it generated a massive $8.3 billion in global sales last year.

From a structural perspective, obefazimod is completely free from the dangerous cardiovascular, infection-rate, and mortality risks that plague traditional JAK inhibitors. Analysts argue that the cancer cases represent a potential labeling restriction rather than an existential safety threat. But with the stock deeply wounded, the leverage has completely shifted from Abivax back to Big Pharma. Suitors who were previously facing an expensive, competitive auction can now afford to sit on their hands, waiting out the cash runway of a clinical-stage target.

The next critical milestone lands in October, when Abivax is scheduled to present the full, granular data set from the ABTECT trial. That presentation will be the first opportunity for independent oncology boards to verify the lack of an organ-specific clustering pattern and firmly decouple the drug from the high-dose malignancies.

In the meantime, CEO Marc de Garidel intends to forge ahead with the regulatory timeline, finalizing a new drug application for formal FDA submission in the fourth quarter of this year, aiming for an independent commercial launch in 2027. Investors will also be tracking mid-2027 phase 2b induction data for the drug's expansion into Crohn's disease. For now, the M&A timeline is frozen; big-pharma buyers will undoubtedly stand on the sidelines until the autumn data provides the absolute proof they need to ensure they aren't buying a multi-billion-dollar legal liability.